SCHEMBL1908177

SCHEMBL1908177

NC(=O)c1nccc(N2CCC(=O)C2=O)c1-c1ccccc1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 1/20 0.35
MAP2K3 P46734 1/20 0.35
IKBKB O14920 1/20 0.35
CDK8 P49336 2/20 0.34
CDK19 Q9BWU1 1/20 0.34
GRM4 Q14833 1/20 0.34
MAPT P10636 1/20 0.33
CASP1 P29466 1/20 0.33
MAP2K1 Q02750 1/20 0.33
CLK4 Q9HAZ1 1/20 0.33
DYRK1B Q9Y463 1/20 0.33
BCAT2 O15382 1/20 0.33
KMT2A Q03164 4/20 0.33
MEN1 O00255 3/20 0.33
KDM4E B2RXH2 2/20 0.33
ALDH1A1 P00352 2/20 0.33
HPGD P15428 2/20 0.33
HSD17B10 Q99714 2/20 0.33
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1908175 0.81 BCAT2 (0.36) ADORA2AMAP2K3IKBKBMAPTCASP1
SCHEMBL1900472 0.80 ADORA2A (0.38) ADORA2AMAP2K3IKBKBGRM4MAPT
SCHEMBL23067310 0.72 MAP2K3 (0.50) ADORA2AMAP2K3IKBKBMAP2K1CLK4
SCHEMBL979253 0.71 MAPK9 (0.38) ADORA2AMAP2K3IKBKBMAP2K1CLK4
SCHEMBL1905180 0.71 NUDT1 (0.51)
SCHEMBL2848953 0.70 ADORA2A (0.46) ADORA2AMAP2K3IKBKBMAP2K1CLK4
SCHEMBL3971167 0.67 ADORA2A (0.41) ADORA2AMAP2K3IKBKBMAP2K1CLK4
SCHEMBL1046126 0.67 CPB1 (0.38) ADORA2ANTRK1PIM1CDC7
Formamide SCHEMBL29058737 0.65 ADORA2A (0.42) ADORA2AMAP2K3IKBKBMAP2K1CLK4
SCHEMBL12495395 0.65 KDM4E (0.47) ADORA2AMAP2K3IKBKBMAPTMAP2K1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110124663-A1 SUBSTITUTED DIOXOPIPERIDINES AND DIOXOPYRROLIDINES AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION VANDERBILT UNIVERSITY 2011-05-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110124663-A1 SUBSTITUTED DIOXOPIPERIDINES AND DIOXOPYRROLIDINES AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION GRM4, GRIA4, GRIK4 ADORA2A 187/4885MAP2K3 2093/4885IKBKB 3391/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.